Sharrell B Lee
Overview
Explore the profile of Sharrell B Lee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
667
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ban Y, Zou Y, Liu Y, Lee S, Bednarczyk R, Sheng J, et al.
bioRxiv
. 2023 Jul;
PMID: 37425795
Significance: This study uncovers the crucial involvement of ribosome biogenesis (RiBi) in the regulation of epithelial and mesenchymal state oscillations in breast cancer cells, which plays a major role in...
2.
Ban Y, Markowitz G, Zou Y, Ramchandani D, Kraynak J, Sheng J, et al.
Nat Cancer
. 2022 Feb;
3(2):262.
PMID: 35122075
No abstract available.
3.
Ban Y, Markowitz G, Zou Y, Ramchandani D, Kraynak J, Sheng J, et al.
Nat Cancer
. 2021 Dec;
2(9):919-931.
PMID: 34917944
Radiation therapy (RT) in combination with immune checkpoint inhibitor (ICI) represents a promising regimen for non-small cell lung cancer (NSCLC), however, the underlying mechanisms are poorly characterized. We identified a...
4.
Ramchandani D, Berisa M, Tavarez D, Li Z, Miele M, Bai Y, et al.
Nat Commun
. 2021 Dec;
12(1):7311.
PMID: 34911956
Copper serves as a co-factor for a host of metalloenzymes that contribute to malignant progression. The orally bioavailable copper chelating agent tetrathiomolybdate (TM) has been associated with a significant survival...
5.
Chan N, Willis A, Kornhauser N, Ward M, Lee S, Nackos E, et al.
Clin Cancer Res
. 2020 Sep;
26(18):5051.
PMID: 32934032
No abstract available.
6.
Yomtoubian S, Lee S, Verma A, Izzo F, Markowitz G, Choi H, et al.
Cell Rep
. 2020 Jan;
30(3):755-770.e6.
PMID: 31968251
Epigenetic changes are increasingly being appreciated as key events in breast cancer progression. However, breast cancer subtype-specific epigenetic regulation remains poorly investigated. Here we report that EZH2 is a leading...
7.
Lourenco A, Ban Y, Crowley M, Lee S, Ramchandani D, Du W, et al.
Cancer Res
. 2019 Nov;
80(2):163-169.
PMID: 31704888
Metastases are responsible for the majority of breast cancer-associated deaths. The contribution of epithelial-to-mesenchymal transition (EMT) in the establishment of metastases is still controversial. To obtain evidence of EMT in...
8.
Markowitz G, Havel L, Crowley M, Ban Y, Lee S, Thalappillil J, et al.
JCI Insight
. 2018 Jul;
3(13).
PMID: 29997286
Success of immune checkpoint inhibitors in advanced non-small-cell lung cancer (NSCLC) has invigorated their use in the neoadjuvant setting for early-stage disease. However, the cellular and molecular mechanisms of the...
9.
Stawowczyk M, Wellenstein M, Lee S, Yomtoubian S, Durrans A, Choi H, et al.
Neoplasia
. 2016 Dec;
19(2):55-64.
PMID: 28013056
Molecularly targeted therapies benefit approximately 15-20% of non-small cell lung cancer (NSCLC) patients carrying specific drug-sensitive mutations. Thus, there is a clinically unmet need for the identification of novel targets...
10.
Chan N, Willis A, Kornhauser N, Ward M, Lee S, Nackos E, et al.
Clin Cancer Res
. 2016 Nov;
23(3):666-676.
PMID: 27769988
Purpose: Bone marrow-derived progenitor cells, including VEGFR2 endothelial progenitor cells (EPCs) and copper-dependent pathways, model the tumor microenvironment. We hypothesized that copper depletion using tetrathiomolybdate would reduce EPCs in high...